Krempa David's Form 4 filing
Eton Pharmaceuticals, Inc.ETON · filed May 27, 2026
- Accession no.
- 0001437749-26-018628
- Filed
- May 27, 2026
- Trade date
- May 22-27, 2026
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not checked
This filing lists 10 non-derivative transactions and 5 derivative transactions. Open-market sales total $3.23M. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Krempa DavidCIK 0001968254 | Officer (Chief Business Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 22, 2026 | Common Stock | MOption exerciseAcquired | +30,591 | $3.58 | +$109,515.78 | 68,046 | Direct | |
| May 22, 2026 | Common Stock | SSaleDisposed | −32,963 | $33.22F1,F7 | −$1,095,030.86 | 35,083 | Direct | |
| May 22, 2026 | Common Stock | SSaleDisposed | −9,315 | $33.88F1,F2 | −$315,592.2 | 25,768 | Direct | |
| May 22, 2026 | Common Stock | SSaleDisposed | −519 | $35.00 | −$18,165 | 25,249 | Direct | |
| May 26, 2026 | Common Stock | MOption exerciseAcquired | +25,000 | $1.38 | +$34,500 | 50,249 | Direct | |
| May 26, 2026 | Common Stock | MOption exerciseAcquired | +12,524 | $1.37 | +$17,157.88 | 62,773 | Direct | |
| May 26, 2026 | Common Stock | SSaleDisposed | −37,524 | $31.49F1,F3 | −$1,181,630.76 | 25,249 | Direct | |
| May 27, 2026 | Common Stock | MOption exerciseAcquired | +12,476 | $1.37 | +$17,092.12 | 37,725 | Direct | |
| May 27, 2026 | Common Stock | MOption exerciseAcquired | +7,203 | $3.58 | +$25,786.74 | 44,928 | Direct | |
| May 27, 2026 | Common Stock | SSaleDisposed | −19,679 | $31.47F1,F5 | −$619,298.13 | 25,249 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 22, 2026 | Common Stock | MOption exerciseDisposed | −30,591 | $0.00 | $0 | 125,609 | Direct | |
| May 26, 2026 | Common Stock | MOption exerciseDisposed | −25,000 | $0.00 | $0 | 0 | Direct | |
| May 26, 2026 | Common Stock | MOption exerciseDisposed | −12,524 | $0.00 | $0 | 12,476 | Direct | |
| May 27, 2026 | Common Stock | MOption exerciseDisposed | −12,476 | $0.00 | $0 | 0 | Direct | |
| May 27, 2026 | Common Stock | MOption exerciseDisposed | −7,203 | $0.00 | $0 | 118,406 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Referenced by the price of 4 transactions in Table I.
- F2
The shares were sold in multiple trades at prices ranging from $33.68 to $34.66. The price reported above reflects the weighted average sales price.
Referenced by the price of 1 transaction in Table I.
- F3
The shares were sold in multiple trades at prices ranging from $31.27 to $32.16. The price reported above reflects the weighted average sales price.
Referenced by the price of 1 transaction in Table I.
- F5
The shares were sold in multiple trades at prices ranging from $31.25 to $31.825. The price reported above reflects the weighted average sales price.
Referenced by the price of 1 transaction in Table I.
- F7
The shares were sold in multiple trades at prices ranging from $32.67 to $33.65. The price reported above reflects the weighted average sales price.
Referenced by the price of 1 transaction in Table I.
Remarks
The reporting person has authorized and designated the named person to file this Form 4 on the reporting person's behalf for indefinite duration.